Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL678151 | 0.93 | ALDH1A1 (0.56) | ALDH1A1TSHRACHERAB9ACYP1A2 | |
| SCHEMBL14887 | 0.93 | — | — | |
| SCHEMBL29391686 | 0.93 | — | — | |
| SCHEMBL8991803 | 0.90 | ALDH1A1 (0.54) | ALDH1A1TSHRACHERAB9ACYP1A2 | |
| Benzene SCHEMBL11895034 | 0.90 | TSHR (0.54) | ALDH1A1TSHRACHERAB9ACYP1A2 | |
| Hydrochloric Acid SCHEMBL5155095 | 0.90 | ALDH1A1 (0.54) | ALDH1A1TSHRACHERAB9ACYP1A2 | |
| SCHEMBL16109755 | 0.90 | ALDH1A1 (0.54) | ALDH1A1TSHRACHERAB9ACYP1A2 | |
| Ammonia Solution, Strong SCHEMBL2441038 | 0.90 | ALDH1A1 (0.54) | ALDH1A1TSHRACHERAB9ACYP1A2 | |
| SCHEMBL7547692 | 0.90 | ALDH1A1 (0.54) | ALDH1A1TSHRACHERAB9ACYP1A2 | |
| SCHEMBL6843315 | 0.90 | ALDH1A1 (0.54) | ALDH1A1TSHRACHERAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2586530-B1 | Mixed bed ion exchange resin with modified cation exchange resin | ROHM & HAAS (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9126195-B2 | Pretreated cation-exchange resin, treation method of the resin, and mixed bed with cation-exchange resin | ROHM AND HAAS COMPANY (US) | 2015-09-08 | — | — | US | disclosed |
| US-20130109769-A1 | PRETREATED CATION-EXCHANGE RESIN, TREATION METHOD OF THE RESIN, AND MIXED BED WITH CATION-EXCHANGE RESIN | ROHM AND HAAS COMPANY (US) | 2013-05-02 | — | — | US | disclosed |
| EP-2586530-A1 | Mixed bed ion exchange resin with modified cation exchange resin | Rohm and Haas Company (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20060239959-A1 | Method for treating hypercholesterolemia with polyallylamine polymers | HOLMES-FARLEY STEPHEN R | 2006-10-26 | — | — | US | disclosed |
| EP-0996454-B1 | USE OF POLYALLYLAMINE POLYMERS FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING HYPERCHOLESTEROLEMIA | GENZYME CORP (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030086898-A1 | Method for treating hypercholesterolemia with polyallylamine polymers | GELTEX PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6423754-B1 | REMOVAL OF BILE SALT | GELTEX PHARMACEUTICALS, INC. | 2002-07-23 | — | — | US | disclosed |
| EP-0996454-A1 | POLYALLYLAMINE POLYMERS FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMACEUTICALS, INC. (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1998057652-A1 | POLYALLYLAMINE POLYMERS FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMACEUTICALS, INC. (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030086898-A1 | Method for treating hypercholesterolemia with polyallylamine polymers | PCSK9, SLC10A1, APOB | ALDH1A1 3987/4885TSHR 4049/4885ACHE 2407/4885 |
| US-20060239959-A1 | Method for treating hypercholesterolemia with polyallylamine polymers | PCSK9, SLC10A1, APOB | ALDH1A1 4319/4885TSHR 3967/4885ACHE 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.